The stakes are high. N.I.H. grants pay for a large share of the basic research conducted at American universities. Breakthroughs that later become drugs, vaccines and treatments routinely begin as N.I.H.-funded laboratory work that no pharmaceutical company would finance on its own, because the payoff is too uncertain and too far in the future.

Scientists have long argued that distance from politics is what makes the system work. Reviewers judge proposals on technical merit. Administrators allocate money based on those judgments. If the White House gains the power to direct grants, critics say, that merit-based firewall weakens.

Why the timing matters

The move fits a broader pattern of assertive executive control over federal science agencies. Policymakers in recent years have debated the balance between political accountability in government-funded research and the scientific independence that agencies like the N.I.H. have historically enjoyed.

Supporters of tighter oversight argue that elected officials should have a say in how taxpayer dollars are spent, especially on research topics that touch on contested social or political questions. Opponents counter that injecting politics into grant-making risks chilling research on subjects that fall out of favor with any given administration.

The practical effects will depend on how the new authority is used. If the White House simply reviews high-level budget priorities, day-to-day science may continue largely unchanged. If officials begin weighing in on individual grants, the character of American biomedical research funding could shift considerably.

The larger picture

The N.I.H. supports work in all 50 states. Its grants sustain laboratories, pay graduate students and postdoctoral researchers, and underpin clinical trials that enroll patients searching for new treatments. Any disruption to that funding stream sends ripples through universities and medical centers well beyond the Washington area.

The story is still developing, and key details remain unclear — including the exact scope of the White House's authority, which grants would be affected, and whether the change will face legal or congressional challenges. What is clear is the direction of travel: more direct political control over the machinery that decides how the United States invests in medical science.

For researchers who depend on N.I.H. funding, and for patients waiting on the results of federally supported research, the central question now is whether the world's largest public funder of biomedical research will continue to choose its projects the way it has for decades — through peer review and expert judgment — or by a new set of rules set at the White House.